Taiko Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending December 2023. For the period, the company expected net sales of JPY 7,900 million, operating profit of JPY 532 million, profit attributable to owners of parent of JPY 50 million and basic earnings per share of JPY 1.15.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
401 JPY | -4.07% | +11.08% | +32.34% |
1st Jan change | Capi. | |
---|---|---|
+32.34% | 134M | |
+21.28% | 44.4B | |
+24.60% | 23.03B | |
+19.22% | 15.14B | |
+12.87% | 13.12B | |
+44.67% | 11.85B | |
-8.33% | 6.99B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.22% | 5.52B |
- Stock Market
- Equities
- 4574 Stock
- News Taiko Pharmaceutical Co.,Ltd.
- Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2023